Isabella Ciccone, MPH

The associate professor of neurology at the Icahn School of Medicine at Mount Sinai talked about the major biomarkers used to track progression in Huntington disease. [WATCH TIME: 5 minutes]

Late breaking data from a phase 1 trial presented at MDS 2025 showed that cell therapy UX-DA001 demonstrated positive efficacy in a woman with moderate-to-advanced Parkinson disease.

At MDS 2025, the senior medical director of UCB's Translational Medicine Neuroscience and Gene Therapy presented data from the ATLANTIS study of glovadalen in patients with Parkinson disease. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 17, 2025.

A phase 3 trial presented at the 2025 MDS Congress suggests that staged, bilateral magnetic resonance–guided focused ultrasound may improve motor symptoms for patients with Parkinson disease who experience motor complications.

A phase 2 study presented at 2025 MDS revealed that onabotulinumtoxinA significantly improved tremor-related disability compared with placebo in patients with upper limb essential tremor.

In phase 2a trial presented at MDS 2025, findings showed that VTX3232 achieved drug levels in plasma and cerebrospinal fluid that exceed the IC90 for NLRP3 inhibition by more than 3-fold.

The assistant professor of neurology at Oregon Health & Science University discussed emerging evidence that aerobic exercise may enhance remyelination in patients with multiple sclerosis. [WATCH TIME: 5 minutes]

New real-world data presented at MDS 2025 demonstrated that foslevodopa/foscarbidopa reduced motor fluctuations and improved quality of life in patients with advanced Parkinson disease over 6 months.

At CNS 2025, the child neurologist at Rady Children's Hospital-San Diego talked about the expanding role of genetics for diagnosis and treatment in pediatric neurology. [WATCH TIME: 5 minutes]

Allison W. Willis, MD, MS, associate professor of neurology at the University of Pennsylvania School of Medicine, provided an overview of hot topics from the ANA 2025 program.

The pediatrician-in-chief at Johns Hopkins Children’s Center shared her reaction to receiving this year’s Bernard Sachs Award in recognition of her contributions to child neurology. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Experts shared their clinical perspectives on trending topics in the treatment and management of multiple sclerosis at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 10, 2025.

Catch up on any of the neurology news headlines you may have missed in September 2025, compiled into 1 place by the NeurologyLive® team.

At CNS 2025, the executive director at the Child Neurology Foundation presented on the importance of collaboration among clinicians and advocacy groups to connect families with care support services. [WATCH TIME: 4 minutes]

A post hoc analysis of the phase 3 EPIDYS trial presented at CNS 2025 revealed that givinostat delayed disease progression in 2 distinct age groups of patients with Duchenne muscular dystrophy.

The neurologist at University of British Columbia discussed how abnormal brain plasticity influences Parkinson progression and highlighted the importance of integrating basic science with clinical care.

Results from the extension phase of the IB1001-203 study, presented as a late-breaker at MDS 2025, suggest N-acetyl-L-leucine prevented worsening of disease progression in patients with ataxia-telangiectasia.

In the MOXIe open-label extension study presented at MDS 2025, omaveloxolone treatment was associated with no significant disease progression in bulbar function or upper limb coordination.

The neurologist at University of British Columbia discussed how breakdowns in brain organization and compensatory mechanisms may influence progression in Parkinson disease. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Final results from a phase 3 extension study presented at ECTRIMS 2025 demonstrated long-term efficacy and safety of ravulizumab-cwvz in patients with neuromyelitis optica spectrum disorder.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 3, 2025.

At ECTRIMS 2025, a staff neurologist at Cleveland Clinic discussed findings from an observational study on long-term safety risks of ocrelizumab in patients with multiple sclerosis. [WATCH TIME: 3 minutes]

At ECTRIMS 2025, the postdoctoral research fellow at the University of Siena in Italy talked about how machine learning could classify multiple sclerosis into biologically distinct subtypes. [WATCH TIME: 5 minutes]

In a phase 3 trial presented at ECTRIMS 2025, ocrelizumab demonstrated noninferior relapse control compared with fingolimod in pediatric patients with relapsing-remitting multiple sclerosis.

Primary results presented at ECTRIMS 2025 suggest that body-weight–adjusted high-dose of ocrelizumab did not further slow disease progression in patients with primary progressive multiple sclerosis.